FX (foreign exchange) effects colour US firms' performance in latest quarter
This article was originally published in Clinica
Amersham's sales of equipment for diagnostics helped prop up ailing revenues from laboratory equipment in the first quarter of 2003. However, the UK-based company suffered from unfavourable foreign exchange (FX) rates. Excluding the effects of this, and of discontinued product lines, sales were up by 6%. In April the company merged its non-core brachytherapy business with US firm Galil Medical's urology business, to sharpen its own focus on medical diagnostics.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.